Some of the human immune system's own defences against the dengue fever virus actually backfire by enabling the virus to infect even more cells, a recent study by scientists from Imperial College London has revealed.
According to the researchers, their new findings could help with the design of a vaccine against the dengue virus.
The study also brings scientists closer to understanding why people who contract dengue fever more than once usually experience more severe and dangerous symptoms the second time around.
Dengue fever is transmitted by a mosquito bite and is prevalent in sub-tropical and tropical regions including South East Asia and South America. Symptoms include high fever, severe aching in the joints and vomiting. The dengue virus can also cause hemorrhagic fever, which can be fatal.
Professor Gavin Screaton, the lead author of the study from Imperial College London, and his colleagues identified a set of antibodies, produced by the human immune system to fight off the dengue virus, that they believe scientists should avoid including in any new vaccine to prevent dengue fever.
The new research shows that these precursor membrane protein (prM) antibodies do not do a very effective job of neutralising the virus. Moreover, these antibodies actually help the virus to infect more cells.